Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Recce Pharmaceuticals Ltd. ( (AU:RCE) ) has provided an update.
Recce Pharmaceuticals Ltd announced the receipt of a US$175,122 rebate from the Canadian Government under the SR&ED Tax Incentive program, which supports R&D activities in Canada. This rebate complements the Australian government’s R&D Tax Incentive, highlighting Recce’s expanding research efforts and the international support for their innovative anti-infective developments.
More about Recce Pharmaceuticals Ltd.
Recce Pharmaceuticals Ltd is a developer of a new class of synthetic anti-infectives aimed at addressing antibiotic-resistant superbugs. Their product pipeline includes patented broad-spectrum synthetic polymer anti-infectives such as RECCE 327, RECCE 435, and RECCE 529, which target serious bacterial and viral infections. The company has received recognition from the World Health Organization and the FDA for its contributions to combating antimicrobial resistance.
YTD Price Performance: -39.58%
Average Trading Volume: 218,685
Technical Sentiment Signal: Buy
Current Market Cap: A$78.45M
For an in-depth examination of RCE stock, go to TipRanks’ Stock Analysis page.